Valeant Pharma (VRX): Cutting PT - BMO

November 14, 2016 7:09 AM EST
Get Alerts VRX Hot Sheet
Price: $14.73 -1.14%

Rating Summary:
    10 Buy, 12 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital Market analyst, Gary Nachtman, reiterated his Market Perform rating on shares of Valeant Pharmaceuticals (NYSE: VRX) but cut his price target to $18 $21 after updating his model to reflect new segment reporting.

The good news is that VRX is attempting to provide greater visibility on its businesses. The bad news is that significant pressures remain in several key areas and the numbers are coming down more meaningfully than anticipated.

The analyst is sticking with his Market Perform rating awaiting updates on potential asset sales to accelerate debt paydown.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $18.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

BMO Capital

Add Your Comment